ArticleBMC cancer2026
Trefoil factor family 3 (TFF3) and migration inducting gene 7 (MIG7) as molecular markers for early detection of endometrial carcinoma micro metastases.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of micrometastatic disease in endometrial carcinoma (EC) remains a major clinical challenge. This study evaluated Migration Inducing Gene 7 (MIG7) and Trefoil Factor Family 3 (TFF3) as minimally invasive biomarkers for EC progression.
methodsMIG7 and TFF3 gene expression and circulating TFF3 protein levels were analyzed in 75 subjects: healthy controls (n = 25), non-metastatic EC (n = 25), and metastatic EC (n = 25). Diagnostic performance was assessed using ROC analysis and logistic regression.
resultsA significant stepwise increase was observed from controls to metastatic EC in MIG7 expression (0.69 vs. 1.97), TFF3 expression (0.38 vs. 2.03), and TFF3 protein levels (0.41 vs. 6.09; P < 0.001). Diagnostic accuracy was high, with AUC values of 0.945, 0.998, and 0.999, respectively. TFF3 gene expression showed the highest balanced performance (96% sensitivity, 100% specificity). MIG7 and TFF3 expression were strongly correlated (r = 0.818, P < 0.001). All markers independently predicted metastatic disease (P < 0.05).
conclusionMIG7 and TFF3 are robust minimally invasive biomarkers for EC detection and metastatic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.